Neurocrine Biosciences, Inc.  today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with ...

The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst ...

There are plenty of reasons to consider coming off the pill, from wanting to conceive to trying to get back in touch with your regular rhythms. But beware the people online who demonise hormonal ...

Different types of birth control pills are available, including low-dose, extended-cycle, and conventional pills. It’s important to talk with a doctor to understand the benefits and risks and ...

Actor Gene Hackman was likely dead for 10 days before he and his wife’s body were discovered at their Santa Fe, N.M., home earlier this week. The Oscar winner and his wife were found dead with ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...

Abortion pill maker enters legal battle over FDA rules by Alejandra O’Connell-Domenech - 02/26/25 2:47 PM ET by Alejandra O’Connell-Domenech - 02/26/25 2:47 PM ET ...

If passed, the EPIC Act would remove the so-called “pill penalty,” which poses a strong disincentive against developing small-molecule drugs, Thomas Kaiser, co-founder and chief scientific officer at ...

The NSW Government has announced that it will implement a twelve-month pill testing trial for music festivals in the state. They will be starting with the 2025 Yours & Owls Festival with the aim of ...

It is important for clinicians to understand the causes and symptoms of tardive dyskinesia to avoid common misdiagnoses and ensure effective management.

By Lisa Lerer The country’s largest manufacturer of abortion pills is wading into the first major legal battle over abortion of President Trump’s second term. The company, GenBioPro ...